PCI Biotech - Photocure's Norwegian cancer-focused drug delivery subsidiary - is to benefit from a wealth of senior management experience with the appointment of Per Walday as its new chief scientific officer.
He will be responsible for project management of all pharmaceutical development and hold pharmaceutical expertise ranging from preclinical research to registration and commercialisation of new products. He has an extensive international network and a thorough understanding of critical success factors in drug development.